Retifanlimab plus chemotherapy for advanced soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests retifanlimab (an immunotherapy that helps your immune system recognize cancer) combined with gemcitabine and docetaxel chemotherapy. It’s for people with advanced soft tissue sarcoma that can’t be safely removed with surgery, aiming to shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-grade soft tissue sarcoma that is metastatic or cannot be safely removed by surgery
- You are age 18 or older and can sign consent for the study
- You must be able to have a tumor biopsy for research if no stored sample is available
- You have measurable tumors on scans, and they have not been selected from an already irradiated area unless that area has clearly worsened since radiation
- You have not had prior chemotherapy or other cancer treatment for advanced/metastatic disease
- Your blood counts, kidney function, and liver function are strong enough for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This Phase 2 trial tests a combination of chemotherapy drugs (Adriamycin and ifosfamide) together with an immunotherapy drug (sintilimab) for advanced soft-tissue sarcoma that can’t be removed by surgery or has stopped responding to standard treatment. It aims to shrink tumors and help control the cancer by boosting the immune system along with chemotherapy.
This Phase 2 study tests toripalimab (an immune therapy) combined with CAV/IE chemotherapy for certain advanced or non-surgically removable sarcomas. It may help shrink tumors and slow disease when standard treatments have failed or don’t exist.
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
Hear when a new Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.